NCT01682187 2024-11-07
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
10 trialsNCT02178358 2022-02-25
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01246986 2021-01-12
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02240433 2020-02-05
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Eli Lilly and Company
Phase 1 Completed
NCT02734160 2019-08-05
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01373164 2018-05-16
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT01220271 2017-02-16
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
Eli Lilly and Company
Phase 1/2 Completed
NCT02304419 2016-10-05
A Study of Galunisertib on the Immune System in Participants With Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02154646 2016-02-10
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
Eli Lilly and Company
Phase 1 Completed
NCT01722825 2014-07-01
Study of LY2157299 in Japanese Participants With Cancer
Eli Lilly and Company
Phase 1 Completed